Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: SMO
Name: smoothened frizzled class receptor
Location: 07q32.1
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00675558 Bariatric Surgery for Morbid Obesity View
NCT01358045 Topical Vitamin D3 Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma View
NCT00981396 The Effect of Emotional Freedom Techniques EFT in Smokers Failing a Smoking Cessation Program View
NCT03434262 SJDAWN St Jude Childrens Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors View
NCT02090504 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome View
NCT02820649 Protective Effects of Exercise Training View
NCT01218477 Dasatinib Combination Therapy With the Smoothened SMO Inhibitor BMS-833923 in Chronic Myeloid Leukemia CML View
NCT02002689 LDE225 for Patients With PTCH1 or SMO Mutated Tumors View
NCT02436408 VISmodegib for ORbital and Periocular Basal Cell Carcinoma View
NCT03052478 Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression View
NCT02523014 Vismodegib FAK Inhibitor GSK2256098 Capivasertib and Abemaciclib in Treating Patients with Progressive Meningiomas View
NCT03767439 Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome View
NCT03855774 Polymorphisms Caffeine and Sleep Disorders View
NCT06357988 Testing GDC-0449 Vismodegib as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors MATCH - Subprotocol T View
NCT01357655 Phase 2 Dasatinib Combo With Smoothened SMO Antagonist BMS-833923 View
NCT02129101 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies View
NCT01350115 Efficacy Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome NBCCS View
NCT02254551 SafetyEfficacy Study of LDE225 Sonidegib Plus Bortezomib in Patients With Relapsed or RelapsedRefractory Multiple Myeloma View
NCT01529450 Pilot LDE225 in Locally Advanced or Metastatic BCC Previously Tx Non-LDE225 Smoothened Inhibitors View